Key Points
- Major shareholder Panacea Innovation Ltd sold 313,446 Atara Biotherapeutics shares for about $3.17 million at an average price of $10.10, reducing its stake by 23.67%.
- Atara Biotherapeutics stock opened at $8.78, giving the company a market cap of $74.72 million, while its shares have traded between $3.92 and $19.15 over the past 52 weeks.
- The company recently reported quarterly EPS of ($0.25), beating estimates, and revenue of $1.60 million, also above expectations; analysts currently rate the stock a Hold with a consensus price target of $9.50.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) major shareholder Innovation Ltd Panacea sold 313,446 shares of the business's stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $10.10, for a total transaction of $3,165,804.60. Following the transaction, the insider owned 1,011,000 shares in the company, valued at $10,211,100. This represents a 23.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Atara Biotherapeutics Price Performance
Atara Biotherapeutics stock opened at $8.78 on Tuesday. The firm has a market capitalization of $74.72 million, a PE ratio of 2.81 and a beta of -0.30. The company's 50-day moving average is $5.39 and its 200-day moving average is $9.21. Atara Biotherapeutics, Inc. has a fifty-two week low of $3.92 and a fifty-two week high of $19.15.
Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last released its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.43. The company had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.70 million. Atara Biotherapeutics had a net margin of 27.07% and a negative return on equity of 79.12%. As a group, analysts expect that Atara Biotherapeutics, Inc. will post 0.2 EPS for the current year.
Analyst Ratings Changes
Several research firms have recently weighed in on ATRA. New Street Research set a $6.00 price objective on shares of Atara Biotherapeutics in a research note on Tuesday, January 13th. Weiss Ratings restated a "sell (d)" rating on shares of Atara Biotherapeutics in a research note on Friday, March 27th. Canaccord Genuity Group set a $13.00 price objective on shares of Atara Biotherapeutics and gave the stock a "buy" rating in a research note on Friday. Finally, Wall Street Zen lowered shares of Atara Biotherapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Atara Biotherapeutics has an average rating of "Hold" and a consensus target price of $9.50.
Get Our Latest Report on Atara Biotherapeutics
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of ATRA. Geode Capital Management LLC grew its stake in Atara Biotherapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company's stock valued at $464,000 after buying an additional 1,457 shares during the last quarter. Marshall Wace LLP bought a new stake in Atara Biotherapeutics in the 2nd quarter valued at about $327,000. Raymond James Financial Inc. bought a new stake in Atara Biotherapeutics in the 2nd quarter valued at about $31,000. Vanguard Group Inc. boosted its holdings in Atara Biotherapeutics by 6.6% in the 3rd quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company's stock valued at $2,915,000 after purchasing an additional 12,677 shares during the period. Finally, GSA Capital Partners LLP boosted its holdings in Atara Biotherapeutics by 33.8% in the 3rd quarter. GSA Capital Partners LLP now owns 26,213 shares of the biotechnology company's stock valued at $376,000 after purchasing an additional 6,622 shares during the period. Institutional investors and hedge funds own 70.90% of the company's stock.
Atara Biotherapeutics Company Profile
(
Get Free Report)
Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.
The company's lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
